Evidence map›Paper›PMID 36069561›Full record

ArticleMicrobiology spectrum2022

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates.

Yu Bai, Qian He, Jinghuan Yang, Shuaiyao Lu, Qunying Mao, Fan Gao, Lianlian Bian, Jialu Zhang, Chaoqiang An, Jianyang Liu and 7 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Research progress on circular RNA vaccines.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yu Bai *Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Qian He *Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Jinghuan Yang *Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Shuaiyao Lu *Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming People's Republic of China.
Qunying MaoDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Fan GaoDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Lianlian BianDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Jialu ZhangDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Chaoqiang AnDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Jianyang LiuDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Xing WuDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Wenhai YuInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming People's Republic of China.
Zhongfang WangGuangzhou Laboratory, Guangzhou, China.
Xiaozhong PengInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming People's Republic of China.
Junzhi WangDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Zhenglun LiangDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Miao XuDivision of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
National Institutes for Food and Drug Control · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the distribution, virulence, and pathogenic characteristics of mutated SARS-CoV-2 to clarify the association between virulence and the viral spreading ability of current and future circulating strains. Chinese rhesus macaques were infected with ancestral SARS-CoV-2 strain GD108 and Beta variant B.1.351 (B.1.351) and assessed for clinical signs, viral distribution, pathological changes, and pulmonary inflammation. We found that GD108 replicated more efficiently in the upper respiratory tract, whereas B.1.351 replicated more efficiently in the lower respiratory tract and lung tissue, implying a reduced viral shedding and spreading ability of B.1.351 compared with that of GD108. Importantly, B.1.351 caused more severe lung injury and dramatically elevated the level of inflammatory cytokines compared with those observed after infection with GD108. Moreover, both B.1.351 and GD108 induced spike-specific T-cell responses at an early stage of infection, with higher levels of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) in the B.1.351 group and higher levels of interleukin 17 (IL-17) in the GD108 group, indicating a divergent pattern in the T-cell-mediated inflammatory "cytokine storm." This study provides a basis for exploring the pathogenesis of SARS-CoV-2 variants of concern (VOCs) and establishes an applicable animal model for evaluating the efficacy and safety of vaccines and drugs.

Indexed as

COVID-19SARS-CoV-2AnimalsCOVID-19 VaccinesDisease Models, AnimalHumansInterferon-gammaInterleukin-17Macaca mulattaTumor Necrosis Factor-alphaVirulenceVirus SheddingCOVID-19 VaccinesInterferon-gammaInterleukin-17Tumor Necrosis Factor-alphanonhuman primateSARS-CoV-2 variantviral distributionviral sheddingvirulence

Identifiers

PMID36069561
PMCPMC9603226
OpenAlexW4295980625

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.